November 9, 2026

Matthew Durdy, chief executive of the Cell and Gene Therapy Catapult (CGT Catapult), has announced his intention to retire in June 2027, following almost 15 years with the organisation, including...

Biological Sciences, Cell and gene therapy, CGT Catapult, Manufacturing, NHS, R&D

October 3, 2026

The UK’s cell and gene therapy sector is at a turning point, with conditions increasingly in place to translate the country’s research strength into company growth and investment, according to...

Cell and gene therapy, Innovation, R&D, Translation gap